PharmGKB Summary: Very Important Pharmacogene Information for RYR1

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2015 Dec 29

PMID 26709912

Citations 5

Authors

Maria L Alvarellos

Ronald M Krauss

Russell A Wilke

Russ B Altman

Teri E Klein

Affiliations

Soon will be listed here.

Citing Articles

Pharmacogenomic considerations for medications in the perioperative setting.

Jhun E, Apfelbaum J, Dickerson D, Shahul S, Knoebel R, Danahey K Pharmacogenomics. 2019; 20(11):813-827.

PMID: 31411557 PMC: 6949515. DOI: 10.2217/pgs-2019-0040.

Personalized medicine: going to the dogs?.

Mealey K, Martinez S, Villarino N, Court M Hum Genet. 2019; 138(5):467-481.

PMID: 31032534 DOI: 10.1007/s00439-019-02020-w.

Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine.

Campion D, Dowell F Front Vet Sci. 2019; 6:22.

PMID: 30854372 PMC: 6396708. DOI: 10.3389/fvets.2019.00022.

Novel Variants in Individuals with -Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings.

Todd J, Razaqyar M, Witherspoon J, Lawal T, Mankodi A, Chrismer I Front Neurol. 2018; 9:118.

PMID: 29556213 PMC: 5845096. DOI: 10.3389/fneur.2018.00118.

Germline genetic variants with implications for disease risk and therapeutic outcomes.

Pasternak A, Ward K, Luzum J, Ellingrod V, Hertz D Physiol Genomics. 2017; 49(10):567-581.

PMID: 28887371 PMC: 5668651. DOI: 10.1152/physiolgenomics.00035.2017.

References

Nelson T, Sweo T . Ca2+ uptake and Ca2+ release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology. 1988; 69(4):571-7. DOI: 10.1097/00000542-198810000-00018. View

Timmins M, Rosenberg H, Larach M, Sterling C, Kraeva N, Riazi S . Malignant hyperthermia testing in probands without adverse anesthetic reaction. Anesthesiology. 2015; 123(3):548-56. DOI: 10.1097/ALN.0000000000000732. View

Takeshima H, Iino M, Takekura H, Nishi M, KUNO J, Minowa O . Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature. 1994; 369(6481):556-9. DOI: 10.1038/369556a0. View

Stewart S, Hogan K, Rosenberg H, Fletcher J . Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet. 2001; 59(3):178-84. DOI: 10.1034/j.1399-0004.2001.590306.x. View

Lopez J, Linares N, Pessah I, Allen P . Enhanced response to caffeine and 4-chloro-m-cresol in malignant hyperthermia-susceptible muscle is related in part to chronically elevated resting [Ca2+]i. Am J Physiol Cell Physiol. 2004; 288(3):C606-12. DOI: 10.1152/ajpcell.00297.2004. View

Bannister R . Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression. Biomed Res Int. 2013; 2013:390493. PMC: 3591246. DOI: 10.1155/2013/390493. View

Feng Q, Wilke R, Baye T . Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012; 13(5):579-94. PMC: 3337775. DOI: 10.2217/pgs.12.11. View

Herrmann-Frank A, LUTTGAU H, Stephenson D . Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story. J Muscle Res Cell Motil. 1999; 20(2):223-37. DOI: 10.1023/a:1005496708505. View

Rebbeck R, Karunasekara Y, Board P, Beard N, Casarotto M, Dulhunty A . Skeletal muscle excitation-contraction coupling: who are the dancing partners?. Int J Biochem Cell Biol. 2013; 48:28-38. DOI: 10.1016/j.biocel.2013.12.001. View

10.

Diaz-Sylvester P, Porta M, Copello J . Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol. 2008; 294(4):C1103-12. PMC: 2465464. DOI: 10.1152/ajpcell.90642.2007. View

11.

Vladutiu G, Isackson P, Kaufman K, Harley J, Cobb B, Christopher-Stine L . Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab. 2011; 104(1-2):167-73. PMC: 3171598. DOI: 10.1016/j.ymgme.2011.07.001. View

12.

Carpenter D, Ringrose C, Leo V, Morris A, Robinson R, Halsall P . The role of CACNA1S in predisposition to malignant hyperthermia. BMC Med Genet. 2009; 10:104. PMC: 2770053. DOI: 10.1186/1471-2350-10-104. View

13.

Pan Z, Brotto M, Ma J . Store-operated Ca2+ entry in muscle physiology and diseases. BMB Rep. 2014; 47(2):69-79. PMC: 3967412. DOI: 10.5483/bmbrep.2014.47.2.015. View

14.

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

15.

Sewry C, Muller C, Davis M, Dwyer J, Dove J, Evans G . The spectrum of pathology in central core disease. Neuromuscul Disord. 2002; 12(10):930-8. DOI: 10.1016/s0960-8966(02)00135-9. View

16.

Robinson R, Carpenter D, Shaw M, Halsall J, Hopkins P . Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006; 27(10):977-89. DOI: 10.1002/humu.20356. View

17.

Alvarellos M, McDonagh E, Patel S, McLeod H, Altman R, Klein T . PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2015; 25(12):622-30. PMC: 4631707. DOI: 10.1097/FPC.0000000000000170. View

18.

Marciante K, Durda J, Heckbert S, Lumley T, Rice K, McKnight B . Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011; 21(5):280-8. PMC: 3076530. DOI: 10.1097/FPC.0b013e328343dd7d. View

19.

Avila G, Dirksen R . Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol. 2001; 118(3):277-90. PMC: 2229502. DOI: 10.1085/jgp.118.3.277. View

20.

McGrew S, Wolleben C, Siegl P, Inui M, Fleischer S . Positive cooperativity of ryanodine binding to the calcium release channel of sarcoplasmic reticulum from heart and skeletal muscle. Biochemistry. 1989; 28(4):1686-91. DOI: 10.1021/bi00430a039. View